New team includes President and CEO Michael Cola formerly with Shire
and Safeguard Scientifics, CFO John Leaman formerly with Shire and
McKinsey, and Global Head of R&D Garry Neil formerly with Apple Tree
Partners and Johnson & Johnson
MISGAV, Israel & SAN FRANCISCO--(BUSINESS WIRE)--
Medgenics, Inc. (NYSE MKT: MDGN and AIM: MEDU, MEDG), developer
of a novel technology for the sustained production and delivery of
therapeutic proteins in patients using their own tissue, announces the
appointment of a new executive leadership team with the goal of
accelerating the development of the company’s gene therapy platform and
maximizing the value of the company’s technology assets. The new
executives are Michael Cola, President and Chief Executive Officer, John
Leaman, M.D., Chief Financial Officer, and Garry Neil, M.D., Global Head
of Research and Development. In addition, on September 13, 2013, Mr.
Cola joined the Medgenics’ Board of Directors.
Andrew L. Pearlman, Ph.D., the company’s Founder and previously the
company’s President and Chief Executive Officer, has retired as of
September 13, 2013 and is continuing to serve on the Board of Directors
and as a senior advisor to the company.
This executive team will be based in the U.S. R&D and manufacturing will
continue to operate in Misgav, Israel and U.S. manufacturing will
continue to operate in San Francisco.
“Mike Cola is a strategic, entrepreneurial and transformational business
leader with a strong record in building shareholder value and broad
experience in life science product development and portfolio management.
Collectively, the new team’s relevant experience and knowledge is
impressive and will be integral to Medgenics’ continued success,” said
Sol J. Barer, Chairman of the Board of Medgenics. “On behalf of the
Board and the entire staff at Medgenics, I extend deepest gratitude to
Andy Pearlman for his many contributions to our company. Andy has
dedicated more than a decade to the development of the Biopump™
technology, and it is through his efforts and leadership that we have
such a strong foundation.”
Dr. Pearlman said, "I am pleased to hand over the reins to Mike, who has
rightfully earned a position of high regard in the biopharmaceutical
industry. Together with John Leaman and Garry Neil, this new executive
leadership represents the ideal complement to the existing Medgenics
team, and brings the expertise to optimize the clinical and commercial
potential of our Biopump technology platform. I am proud and honored to
continue as a Director for this outstanding and expanded team, and as an
advisor to assist them. Medgenics’ future looks brighter than ever.”